Fig. 2From: Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV studyKaplan–Meier analysis of overall survival (A) and subgroup analyses of overall survival (B) according to baseline characteristics in the intention-to-treat (ITT) populationBack to article page